

ETHOS-PUSH: Hemangiosarcoma Study

PET OWNER'S GUIDE

UPDATED: 6/2021



ETHOS DISCOVERY

Ethos Discovery is a nonprofit incubator of scientific innovation. Our mission is to improve health outcomes for both human and pet patients with complex medical problems.

TABLE OF CONTENTS

01	INTRODUCTION	1
02	HEMANGIOSARCOMA STUDY	2
03	WHAT TO EXPECT	3
04	CURING THIS DISEASE	5

To learn more about Ethos Discovery, please
visit our website [**ethosdiscovery.org**](https://ethosdiscovery.org)





As a result of your dog's diagnosis of splenic hemangiosarcoma, he/she may be eligible for enrollment into the Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH) trial.

Hemangiosarcoma is a complex disease but we are confident that through Ethos-PUSH we will be able to deliver curative outcomes. Through our collaborations across the country with leading scientists in the fields of oncology and cancer genomics, we will shed new light on this disease which will continue to guide our path towards identifying a cure. Each dog enrolled on Ethos-PUSH will be participating in this endeavor.

BY PARTICIPATING IN THIS STUDY YOUR DOG IS:

- RECEIVING THE BEST CARE AVAILABLE
- DELIVERING A CURE TO FUTURE DOGS
- IMPROVING OUTCOMES FOR HUMANS

HEMANGIOSARCOMA STUDY

DOGS TREATED AS PART OF THE HEMOABDOMEN STUDY WHO ARE DIAGNOSED WITH SPLENIC HEMANGIOSARCOMA MAY BE ELIGIBLE TO CONTINUE ON TO THE HEMANGIOSARCOMA STUDY.

The Hemangiosarcoma Study seeks to understand how genomic subtypes of hemangiosarcoma (i.e. the underlying genetic mutations that lead to cancer development) should be optimally treated based on our current understanding of the genomics of this disease.

TREATMENT GROUPS

The Hemangiosarcoma Study study participants will be randomized into one of four treatment groups:

- **Doxorubicin** - Current standard injectable chemotherapy treatment for hemangiosarcoma.
- **Rapamycin** - Human oral cancer drug given concurrently with doxorubicin chemotherapy.
- **Sorafenib** - Human oral cancer drug given concurrently with doxorubicin chemotherapy.
- **Oral Paclitaxel** - Novel two drug combination given orally on its own with no injectable drugs.

**ALL DOGS IN THE STUDY WILL RECEIVE ACTIVE DRUGS.
THERE ARE NO PLACEBO TREATMENTS INCLUDED IN THE STUDY.**

THERAPEUTICS SELECTED

The novel treatments included in the Hemangiosarcoma Study have been selected based on our current understanding of the genomics of hemangiosarcoma. These treatments are distinct from most conventional chemotherapy drugs used to treat cancer in dogs.

We have carefully conducted previous studies with these drugs in dogs with cancer to identify the optimal doses to safely treat your dog. The cost of treatment is fully covered by your participation in the study.

WHAT TO EXPECT

OUTSTANDING QUALITY OF LIFE

Based on our previously completed studies, you should expect an outstanding quality of life for your dog while on therapy.

Treating cancer in all species is challenging and is associated with unavoidable but infrequent short-term risks.

Your dog will receive care from an experienced Veterinary Oncologist and our entire study team throughout the length of the study. We understand that each individual dog may handle treatment differently. If the treatment your pet receives is not well tolerated initially, dose adjustments will be made to define an appropriate dose for your dog.

If you would like to withdraw your dog from our study at any time, for any reason, you may do so without penalty. We want what's best for you and your family.

GOLD STANDARD CARE AND MONITORING

In addition to treatment, dogs participating in the Hemangiosarcoma Study will receive state-of-the-art monitoring and follow up care, including:

- Follow up blood tests
- Imaging studies
- Examinations relating to your dog's cancer care over the study period of 1 year.

Study dates were selected to provide the best possible care for your dog. All dogs participating in this study must be treated and monitored according to the Hemangiosarcoma Study schedule (please see schedule in the informed consent form).



YOU AND YOUR DOG ARE HELPING CURE THIS DISEASE IN DOGS

This study is following a road map used to improve survival in childhood leukemia patients.

This road map starts with new knowledge and delivers the hope of this new knowledge through clinical trials to as many patients as possible.

Enrolling your eligible dog in this clinical trial will deliver the very best care that exists in veterinary oncology to your dog and will provide the needed knowledge to cure this disease for future generations of canine patients.

THANK YOU

YOU AND YOUR DOG ARE HELPING HUMAN PATIENTS WITH THIS CANCER

The mission of Ethos Discovery is to improve health outcomes for both human and pet patients with complex medical problems.

Hemangiosarcoma in dogs is called angiosarcoma in humans. In humans, this cancer can occur in any part of the body, but most often occurs on the face and scalp of older patients. Similar to the disease in dogs, this cancer is highly aggressive and new treatments are needed.

Ethos Discovery has included human cancer research teams in the design and conduct of this study. These human cancer research teams stand ready to use the results from our study and will apply the new knowledge gained to the treatment of humans with angiosarcoma. Accordingly, through this study your dog is receiving the best care available, delivering a cure to future dogs, and improving outcomes for humans.

A large, stylized graphic of a hexagon with a thick border, composed of two interlocking shapes that create a 3D effect. The hexagon is centered on the page and serves as a background for the main text.

ETHOS

D I S C O V E R Y

100% OF ALL DONATIONS SUPPORT SCIENTIFIC RESEARCH.